Michael  Kauffman net worth and biography

Michael Kauffman Biography and Net Worth

Director of Kezar Life Sciences
Michael Kauffman, M.D., Ph.D., has served as a member of our Board of Directors since December 2016. Dr. Kauffman co-founded Karyopharm Therapeutics, Inc. in 2008 and has served as its Chief Executive Officer since January 2011 and as a member of its Board of Birectors since 2008. Dr. Kauffman also served as the President of Karyopharm Therapeutics, Inc. from January 2011 to December 2013 and as its Chief Medical Officer from December 2012 to December 2013. Prior to that, Dr. Kauffman served as the chief medical officer at Onyx Pharmaceuticals, Inc., and as Chief Medical Officer of Proteolix, Inc. Dr. Kauffman also served as President and Chief Executive Officer of both Epix Pharmaceuticals, Inc. and Predix Pharmaceuticals, Inc., and was an operating partner at Bessemer Venture Partners. Dr. Kauffman also held a number of senior positions at Millennium Pharmaceuticals, Inc. and Biogen Idec, Inc. Dr. Kauffman has served on the board of directors of Verastem Inc., a publicly held biopharmaceutical company, since November 2012, and Infinity Pharmaceuticals Inc., a publicly held biopharmaceutical company, since 2017. Dr. Kauffman received his B.A. in Biochemistry from Amherst College and his M.D. and Ph.D. in Biochemistry, Cellular and Molecular Biology degrees from Johns Hopkins Medical School. Dr. Kauffman completed his residency in internal medicine at Beth Israel Deaconess Hospital and was a fellow in Rheumatology at Massachusetts General Hospital.

What is Michael Kauffman's net worth?

The estimated net worth of Michael Kauffman is at least $500,498.00 as of October 12th, 2020. Dr. Kauffman owns 555,122 shares of Kezar Life Sciences stock worth more than $500,498 as of March 29th. This net worth evaluation does not reflect any other assets that Dr. Kauffman may own. Learn More about Michael Kauffman's net worth.

How do I contact Michael Kauffman?

The corporate mailing address for Dr. Kauffman and other Kezar Life Sciences executives is 4000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. Kezar Life Sciences can also be reached via phone at (650) 822-5600 and via email at [email protected]. Learn More on Michael Kauffman's contact information.

Has Michael Kauffman been buying or selling shares of Kezar Life Sciences?

Michael Kauffman has not been actively trading shares of Kezar Life Sciences within the last three months. Most recently, Michael Kauffman sold 5,000 shares of the business's stock in a transaction on Monday, January 3rd. The shares were sold at an average price of $16.45, for a transaction totalling $82,250.00. Learn More on Michael Kauffman's trading history.

Who are Kezar Life Sciences' active insiders?

Kezar Life Sciences' insider roster includes Marc Belsky (CFO & Sec. ), John Fowler (Co-Founder), and Michael Kauffman (Director). Learn More on Kezar Life Sciences' active insiders.

Michael Kauffman Insider Trading History at Kezar Life Sciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/3/2022Sell5,000$16.45$82,250.00View SEC Filing Icon  
See Full Table

Michael Kauffman Buying and Selling Activity at Kezar Life Sciences

This chart shows Michael Kauffman's buying and selling at Kezar Life Sciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Kezar Life Sciences Company Overview

Kezar Life Sciences logo
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $0.90
Low: $0.88
High: $0.94

50 Day Range

MA: $0.91
Low: $0.80
High: $1.05

2 Week Range

Now: $0.90
Low: $0.67
High: $3.37

Volume

1,161,759 shs

Average Volume

861,360 shs

Market Capitalization

$65.64 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.48